US SEC Filings Daily Market Digest — August 14, 2026
The August 14, 2026, filing batch reveals a market bifurcated between aggressive growth investments in AI, space, and critical minerals (e.g., Hancock Prospecting's $5.7B portfolio, Blue Sparrow's $10.3B tech-heavy fund) and a defensive, hedging posture among many institutional managers (e.g., Lonestar Capital's 53% put exposure, Yaupon Capital's $1.44B SPY put). Period-over-period data from operating companies shows a stark contrast: SaaS leader Intapp grew revenue 15% YoY but saw net losses widen 127%, while micro-cap SEATech and American Picture House remain cash-burning shells with no revenue. Insider activity is limited, but management changes at Lifeward (CFO departure) and Skye Bioscience (near-total dilution via reverse merger) signal significant governance shifts. Capital allocation trends are mixed, with Riverview Bancorp increasing buybacks while Edible Garden invests in growth. The most critical development is Skye Bioscience's acquisition of Redx Pharma, creating a new fibrosis leader with ~$125M in committed funding, though pre-deal shareholders face massive dilution. Portfolio-level patterns show a clear rotation toward SPACs and special situations (Shaolin Capital, Ghisallo Capital) and a defensive tilt with significant put buying on major indices, suggesting institutional caution on near-term market direction.